A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review

A Multi-Country, Real-World Study to Explore Treatment Patterns, Effectiveness and Healthcare Resource Utilization for Patients Diagnosed With Myelofibrosis Through Chart Review

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05444972

Acronym

METER

Enrollment

998

Registered

2022-07-06

Start date

2022-08-23

Completion date

2023-11-14

Last updated

2023-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myelofibrosis

Keywords

Myelofibrosis, Cancer

Brief summary

Myelofibrosis (MF) is a rare blood cancer, characterized by extensive fibrosis (scarring) of the bone marrow. It is one of a group of cancers known as myeloproliferative neoplasms (MPNs) in which bone marrow cells that produce blood cells develop and function abnormally. This study will evaluate treatment patterns, treatment outcomes, healthcare resource utilization in adult participants with Myelofibrosis. Data from approximately 1000 participants will be collected. No participants will be enrolled in this study. Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the observation period is up to 156 weeks. There is no additional burden for participants in this trial. All visits must be completed prior to data extraction and participants will be followed for up to 156 weeks.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Treated for myelofibrosis (MF) \[primary myelofibrosis (PMF) and secondary myelofibrosis (SMF)\]. * Must have initiated their first treatment on or after the first date when ruxolitinib was approved in their country of residence and no later than 31 December 2021.

Exclusion criteria

\- Having received MF treatment in a clinical trial setting.

Design outcomes

Primary

Measure	Time frame	Description
Time from Diagnosis of Myelofibrosis (MF) to Initial Treatment	Up to Week 156	Time from diagnosis of MF to initial treatment.
Duration of Initial Treatment	Up to Week 156	Duration of initial treatment.
Duration of Second Treatment	Up to Week 156	Duration of second treatment.
Duration of Subsequent Treatments	Up to Week 156	Duration of subsequent treatments.

Countries

Argentina, Australia, Brazil, Canada, Colombia, Greece, Italy, Mexico, Poland, Portugal, Romania, Taiwan, Turkey (Türkiye), United States

Outcome results